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Available online 1 December 2015Fibrodysplasia ossiﬁcans progressiva (FOP) is an extremely rare, autosomal dominant transmitted genetic dis-
ease. Patients experience progressive bone formation replacing tendons, ligaments, muscle and soft tissue.
Cause of FOP are gain-of-functionmutations in the BoneMorphogenetic Protein (BMP) receptorActivin A receptor
type 1 (ACVR1) (Kaplan et al., 2008). The most common mutation is R206H, which leads to the substitution of
codon 206 from arginine to histidine (Shore et al., 2006).
Here, we describe the derivation and characterization of two hiPSC lines from two FOP patients, both carrying the
mutation R206H. Cells were isolated from urine and reprogrammed using integration free Sendai virus vectors
under deﬁned conditions.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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2. Materials and methods
2.1. Ethics statement
This work was approved by the Ethics Commission of the
Charité—Universitätsmedizin Berlin (EA2/047/14).
2.2. Isolation of cells from urine
Isolation of cells from urine was performed as described by Zhou
et al. (2012). Brieﬂy, to obtain urinary cells, approximately 100 to
200 ml of urine were collected and centrifuged at 400 g for 10 min.
The supernatant was discarded and the cell pellet was washed with
10ml PBS containing 100U/ml of penicillin and 100 μg/ml streptomycin
(Lonza). Following another centrifugation, the pellet was resuspended
in 2 ml of primary medium (Dulbecco's Modiﬁed Eagle Medium
(DMEM) high glucose (Life Technologies) and Ham's F12 (Biochrom)
(1:1), 10% (vol/vol) Fetal Bovine Serum (FBS) (Biochrom), 100 U/ml
penicillin, 100 μg/ml streptomycin (Lonza), 100 μg/ml normocin
(InvivoGen) and the Renal Cell Growth Medium (REGM) SingleQuot
kit supplements (Lonza)) and seeded in one well of a 12-well plate
(Corning) coated with 0,1% (w/t) gelatin (Gibco). The following threethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
List of primers used for Sendai testing, germ layer PCR.




SeV Forward GGA TCA CTA GGT GAT ATC GAG C 181
Reverse ACC AGA CAA GAG TTT AAG AGA TAT GTA TC
SeV-Klf4 Forward TTC CTG CAT GCC AGA GGA GCC C 410
Reverse AAT GTA TCG AAG GTG CTC AA
SeV-cMyc Forward TAA CTG ACT AGC AGG CTT GTC G 532
Reverse TCC ACA TAC AGT CCT GGA TGA TGA TG
SeV-KOS Forward ATG CAC CGC TAC GAG TGA GCG C 528
Reverse ACC TTG ACA ATC CTG ATG TGG
Hu18SRNA Forward GTA ACC CGT TGA ACC CCA TT 151
Reverse CCA TCC AAT CGG TAG TAG CG
Pluripotency and differentiation marker
Nanog Forward AAGGTCCCGGTCAAGAAACAG 237
Reverse CTTCTGCGTCACACCATTGC
Brachyury Forward TAAGGTGGATCTTCAGGTAGC 252
Reverse CATCTCATTGGTGAGCTCCCT
Goosecoid Forward AACGCGGAGAAGTGGAACAAG 89
Reverse CTGTCCGAGTCCAAATCGC
Mixl1 Forward CTGTTCCCCTCTCTCTGAAGA 67
Reverse GGCAGAAAAGATGTGTTCCTCC
Foxa2 Forward GGAGCAGCTACTATGCAGAGC 83
Reverse CGTGTTCATGCCGTTCATCC
Sox17 Forward GTGGACCGCACGGAATTTG 94
Reverse GGAGATTCACACCGGAGTCA
Nestin Forward TTGCCTGCTACCCTTGAGAC 145
Reverse GGGCTCTGATCTCTGCATCTAC
Sox1 Forward CAGTACAGCCCCATCTCCAAC 287
Reverse GCGGGCAAGTACATGCTGA
NeuroD Forward GCCCCAGGGTTATGAGACTATCACT 523
Reverse CCGACAGAGCCCAGATGTAGTTCTT
Otx2 Forward TGTAGAAGCTATTTTTGTGGGTGA 98
Reverse GAGCATCGTTCCATCTAACTTTTT
Pax6 Forward TGTCCAACGGATGTGTGAGT 162
Reverse TTTCCCAAGCAAAGATGGAC
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the medium was removed and replaced by renal epithelial/mesenchy-
mal cell (RE/MC) proliferation medium (1:1 mixture of Renal Cell
Growth Medium (REBM) medium supplemented with REGM
SingleQuots (Lonza) and DMEM high glucose supplemented with 10%
(vol/vol) FBS, 1% (vol/vol) GlutaMAX, 1% (vol/vol) non-essential
amino acids (NEAA) (all Life Technologies), 100 U/ml penicillin,
100 μg/ml streptomycin, 5 ng/ml basic ﬁbroblast growth factor
(bFGF), 5 ng/ml platelet derived growth factor AB (PDGF-AB) and
5 ng/ml human epidermal growth factor (hEGF) (all Peprotech)). Sub-
sequently, half of the culture medium was changed every day. Once
cells reached 90% density, they were passaged using TrypLE Select
(Life Technologies) with a splitting ratio of 1:4–1:6 and expanded for
a maximum of ﬁve passages.
2.3. Reprogramming
Reprogramming was performed using Sendai virus vectors
(CytoTune-iPS 2.0 Reprogramming Kit, Life Technologies) (Fusaki
et al., 2009). Brieﬂy, 5 × 104 cells, seeded in one well of a 24-well
plate coated with gelatin and cultured in RE/MC proliferation medium,
were transduced using the vectors polycistronic Klf4–Oct3/4–Sox2,
cMyc, and Klf4. After addition of the virus, the plate was centrifuged at
800 g for 20 min at room temperature. After 24 hmediumwas replaced
by fresh RE/MC proliferation medium and cells were cultured for seven
days with medium changes every other day. On day 8 after transduc-
tion, cells were passaged using TrypLE Select and seeded with a density
of 3 × 104 cells/well in RE/MC proliferation medium onto a 6-well plate
coated with Geltrex (Life Technologies). On the next day medium was
changed to Essential 8 (E8) medium (Life Technologies) supplemented
with100 U/ml penicillin, 100 μg/ml streptomycin and replaced every
day until hiPSC colonies appeared. Individual colonies were picked
using a pipette tip and expanded in E8 medium on plates coated with
Geltrex.
2.4. Test for absence of the reprogramming vector
After passage 12, iPSC lines were tested for absence of the Sendai
reprogramming vectors by performing a RT-PCR,which detects the Sen-
dai virus (SeV) genome and the transgenes. For that, total RNA was iso-
lated using an RNeasy Plus Mini Kit (Qiagen) following manufacturer's
instructions and cDNA was generated by reverse transcription using
the TaqMan Reverse Transcription Reagents (Applied Biosystems).
RT-PCR were performed as suggested by the manufacturer of the
reprogramming kit (Life Technologies):
95 °C for 5 min, followed by 35 cycles of 95 °C for 30 s, 55 °C for 30 s
and 72 °C for 30 s, ﬁnally 72 °C for 10 min. The primer sequences for
Sendai virus genome (SeV), krueppel-like factor 4—transgene (SeV-
Klf4), cMyc—transgene (SeV-cMyc), and Klf4-Oct 3/4-SOX2—transgene
(SeV-KOS) are given in the table below (Table 1). As an internal control
the housekeeping gene for the 18 s ribosomal RNA was detected. PCR
productswere analyzed by 2% agarose gel electrophoresis (Life Technol-
ogies) (Fig. 2).
2.5. Culture of iPSC
The hiPSCwere cultured in E8medium supplementedwith 100U/ml
penicillin and 100 μg/ml streptomycin in 6 well dishes coated with
Geltrex and routinely passaged using 0.5 mM EDTA (Life Technologies)
in PBS every 5–7 days at a ratio of ~1:10.
2.6. Immunoﬂuorescence staining for pluripotency markers
For staining hiPSC were grown on 96 well imaging plates
(CellCarrier, Perkin Elmer) in E8 medium. After three days, cells were
ﬁxed with Cytoﬁx reagent, followed by blocking and permeabilizationwith PermWash reagent (both BD) supplemented with 5% FBS. Then,
cells were incubated with dye-conjugated antibodies for octamer tran-
scription factor 3/4 (Oct3/4) (PerCP-Cy7, BD, 1:100), stage speciﬁc em-
bryonic antigen 4 (SSEA4) (FITC, R&D; 1:100), tumor rejection antigen
1–60 (Tra-1-60) (DyLight 550, Novus Biologicals, 1:100) and Tra-1-81
(DyLight 650, Novus Biologicals, 1:100). Nuclei were stained with
Hoechst 33,342 (2.5 μg/ml in PBS, Invitrogen). Microscopic analysis
was performed with an Operetta high content imaging system (Perkin
Elmer) (Fig. 1).
2.7. In vitro differentiation into the three germ layers
Undirected differentiation of iPSC into the three germ layers was
performed by generation of embryoid bodies (EBs) using AggreWell
plates (StemCell Technologies). EBs were cultured in DMEM Low
Glucose supplemented with 10% FBS, 2 mM/ml L-Glutamine, 100 U/ml
of penicillin and 100 μg/ml streptomycin for 10 days. Medium was
changed every other day.
2.8. RT-PCR of markers for pluripotency and the three germ layers
500 ng of total RNA from EBswas reverse transcribed into cDNA. 1 μl
of this reactionwas subjected to Polymerase Chain Reaction (PCR) using
primers speciﬁc for NANOG, brachyury, goosecoid, mix paired-like
homeobox (Mixl1), forkhead-box-protein A2 (FoxA2), 6 = SRY (Sex
Determining Region Y)-Box 17 (Sox17), Sox1, nestin, NEUROD,
orthodenticle homeobox 2 (Otx2), and Paired box protein 6 (Pax6)
Fig. 1.Morphology of primary cells, iPSC and expression of pluripotencymarkers in iPSC. [A+D] Phase contrast images of primary cells derived from urine. [B+ E] Phase contrast images
of reprogrammed iPSC. [C + F] Staining of pluripotency markers Anti-stage speciﬁc embryonic antigen 4 (SSEA4) (cell surface), Anti-Tra-1-60 (cell surface), Anti-Oct3/4 (nuclear), Anti-
Tra-1-81 (cell surface), Hoechst33342 (nuclear) and overlay of all markers. (Upper scale bar = 100 μm, lower scale bar =50 μm).
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cles of 96 °C for 30 s, 58 °C for 30 s and 72 °C for 30 s. Final stepwas 72 °C
for 7 min. PCR products were analyzed using a by electrophoresis in an
2% agarose gel (Fig. 3).Fig. 2. Test for absence of Sendai virus. RT-PCR for reprogramming vectors in [A] positive cont
krueppel-like factor 4—transgene (SeV-Klf4), 3 = cMyc—transgene (SeV-cMyc), 4 = Klf4-Oct
Fig. 3. Differentiation capacity of iPSC into all three germ layers. RT-PCR for pluripotency and ge
Goosecoid, 4 = Mix Paired-Like Homeobox (Mixl1), 5 = Forkhead-Box-Protein A2 (FoxA2), 6
10 = Orthodenticle homeobox 2 (Otx2), 11 = Paired box protein 6 (Pax6).2.9. Sequencing
To conﬁrm presence of the FOP mutation R206H in the hiPSC, se-
quencing was performed. For that, genomic DNA (gDNA) was isolatedrol [B] negative control [C] BCRTi001-A and [D] BCRTi002-A. 1 = Sendai virus (SeV), 2 =
3/4-SOX2—transgene KOS (SeV-KOS), 5 = 18 sRNA control.
rm layer markers for [A] BCRTi001-A and [B] BCRTi002-A. 1= Nanog, 2= Brachyury, 3=
= SRY (Sex Determining Region Y)-Box 17 (Sox17), 7 = Nestin, 8 = Sox1, 9 = NeuroD,
Fig. 4. Sequencingof FOPmutation R206H.HeterozygousmutationGuanine to Adenine, leading to exchange of aminoacidArginine toHistidine at position 206 in amino acid sequencewas
conﬁrmed in [A] BCRTi001-A and [B] BCRTi002-A.
Fig. 5. Karyotyping of the cell lines. Karyotyping was performed using the KaryoLite™ BoBs™ assay. Both iPSC lines (a) BCRTi001-A, (b) BCRTi002-A showed a normal karyotype. The red
and blue lines indicate chromosomal signal ratios against female (red) andmale (blue) referenceDNAwith normal karyotypes. For thenormal chromosomes both the ratios against female
and male references should be in the reference area (green lines) around a value of 1, whereas for the abnormal karyotype both signals should be outside the reference area.
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tions. 50 ng of gDNA served as a template in a touch-down PCR with this
program: 94 °C for 30 s, followed by 25 cycles of 95 °C for 30 s, 59–56 °C
for 30 s and 68 °C for 30 s, ﬁnally 68 °C for 7 min (primer sequences
F: CCAGTCCTTCTTCCTTCTTCC, R: AGCAGATTTTCCAAGTTCCATC) (Shore
et al., 2006). Quality of ampliﬁcation products was analyzed using a 1%
agarose gel and sequenced using a 3730 DNA Analyzer (Life Technolo-
gies). Resulting sequence information was analyzed with DNASTAR soft-
ware (Fig. 4).
3. Veriﬁcation and authentication
3.1. Karyotyping
Karyotyping was carried out using KaryoLite™ BoBs™ (Perkin
Elmer) (Lund et al., 2012). From each sample at least 240 ng of gDNA
was used as a starting material. The samples were processed according
to the manufacturer's instructions. Brieﬂy, gDNA was labelled with
Biotin, puriﬁed and hybridized to beads with complementary bacterial
artiﬁcial chromosome (BAC) probes. After washing and reporter
(streptavidin-PE) binding, the ﬂuorescent signals were measured with
a Bio-Plex 200 system (BioRad). Results were analyzed using BoBsoft™analysis software (Perkin Elmer). As references female and male gDNA
(Promega) were used. A sample was deﬁned as ‘normal disomic’,
when the ﬂuorescent ratio was ~1.0 for all loci analyzed (Fig. 5).
3.2. Fingerprinting
For identity and purity veriﬁcation of the iPSC lines, Short Tandem
Repeat (STR) analysis was performed from the primary cells and the
reprogrammed iPSC by ampliﬁcation of 10 loci from the Combined
DNA Index Systems (CODIS), namely D16S539, D7S820, CSF1PO,
D5S818, TPOX, D13S317, vWA, HUMTH01, DXS101 and DYS393. For
personalized data protection reasons, resulting data are only available
in the hPSCreg database under controlled access.
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